Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financials

The fair value of the asset has been independently determined by applying the so-called "income approach" which calculates the value on the basis of discounted future economic benefits expected to be provided by the asset. The fair value of the asset has been independently determined by applying the so-called "income approach" which calculates the value on the basis of discounted future economic benefits expected to be provided by the asset. The intangible asset will be subject to regular...

The fair value of the asset has been independently determined by applying the so-called "income approach" which calculates the value on the basis of discounted future economic benefits expected to be provided by the asset.

The intangible asset will be subject to regular amortization over its useful life, currently expected to be at least 10 years.

The write-up of the intangible asset will not impact the consolidated IFRS financial statements of the Hansa Group.

Baker & McKenzie Amsterdam NV acted as the independent valuation expert and Fenix Advisory AB acted as accounting advisor.

This press release constitutes inside information that Hansa Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact person set out below, at the time stated by the Company's news distributor, Cision at the publication of this press release.

CONTACT:

For further information, please contact:

Klaus Sindahl, VP Head of Investor Relations
M: +46 (0) 709–298 269
E: klaus.sindahl@hansabiopharma.com

Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802
E: stephanie.kenney@hansabiopharma.com

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-ab-recognizes-a-write-up-of-sek-1-430-billion-in-intangible-assets-related-to-idefirix-in-the-financial-statements-of-the-parent-company---no-impact-on-the-consolidated-financials-301869525.html